Crowley, M. J., McGuire, D. K., Alexopoulos, A.-S., Jensen, T. J., Rasmussen, S., Saevereid, H. A., … Buse, J. B. (2020). Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial. Diabetes Care, 43(9), e108–e110. https://doi.org/10.2337/dc20-0437

Crowley, Matthew J., Darren K. McGuire, Anastasia-Stefania Alexopoulos, Thomas Jon Jensen, Søren Rasmussen, Hans A. Saevereid, Subodh Verma, and John B. Buse. “Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial.” Diabetes Care 43, no. 9 (September 2020): e108–10. https://doi.org/10.2337/dc20-0437.

Crowley MJ, McGuire DK, Alexopoulos A-S, Jensen TJ, Rasmussen S, Saevereid HA, et al. Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial. Diabetes Care. 2020 Sep;43(9):e108–10.

Crowley, Matthew J., et al. “Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial.” Diabetes Care, vol. 43, no. 9, Sept. 2020, pp. e108–10. Pubmed, doi:10.2337/dc20-0437.

Crowley MJ, McGuire DK, Alexopoulos A-S, Jensen TJ, Rasmussen S, Saevereid HA, Verma S, Buse JB. Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial. Diabetes Care. 2020 Sep;43(9):e108–e110.